MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ
1.600
+0.030
+1.91%
After Hours: 1.570 -0.03 -1.88% 19:57 05/20 EDT
OPEN
1.610
PREV CLOSE
1.570
HIGH
1.618
LOW
1.535
VOLUME
847.64K
TURNOVER
0
52 WEEK HIGH
2.310
52 WEEK LOW
0.6200
MARKET CAP
200.81M
P/E (TTM)
-6.7825
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATOS last week (0513-0517)?
Weekly Report · 19h ago
Atossa Therapeutics Last Patient Its Phase 2 Karisma-Endoxifen Clinical Trial Recieved Their Final Dose
Last patient in the Company's Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in oncology. The Company's focus is breast cancer with a focus on breast cancer.
Benzinga · 5d ago
BRIEF-Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
Reuters · 5d ago
Atossa Therapeutics’ Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating
TipRanks · 6d ago
Cantor Fitzgerald Reiterates Overweight on Atossa Therapeutics
Benzinga · 6d ago
Atossa Therapeutics files for $100M mixed shelf offering
Atossa Therapeutics files for $100M mixed shelf offering May 13, 2024. The company filed a prospectus related to a proposed $100 million mixed shelf offer. Atossa's stock is down 1.7% to $8.05.
Seeking Alpha · 05/13 20:38
ATOSSA THERAPEUTICS FILES FOR MIXED SHELF OF UP TO $100 MLN - SEC FILING
Reuters · 05/13 20:06
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024
Atossa Therapeutics reported earnings per share of -5 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -7 cents. Atossa reported results for the fourth quarter of 2015.
Investorplace · 05/13 18:52
More
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Webull offers Atossa Therapeutics Inc stock information, including NASDAQ: ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.